{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T19:35:58Z","timestamp":1785612958862,"version":"3.56.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Histochemica"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.acthis.2023.152024","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T18:21:48Z","timestamp":1679422908000},"page":"152024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pulmonary 5-HT2B receptor expression in fibrotic interstitial lung diseases"],"prefix":"10.1016","volume":"125","author":[{"given":"Anna","family":"L\u00f6fdahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Nybom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Wig\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"Dellgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Brunnstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Wengl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Westergren-Thorsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.acthis.2023.152024_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154516","article-title":"Immune inflammation and disease progression in idiopathic pulmonary fibrosis","volume":"11","author":"Balestro","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.acthis.2023.152024_bib2","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.acthis.2023.152024_bib3","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/1756-185X.13386","article-title":"5-HT2 and 5-HT2B antagonists attenuate pro-fibrotic phenotype in human adult dermal fibroblasts by blocking TGF-beta1 induced non-canonical signaling pathways including STAT3: implications for fibrotic diseases like scleroderma","volume":"21","author":"Chaturvedi","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.acthis.2023.152024_bib4","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1084\/jem.20101629","article-title":"Platelet-derived serotonin links vascular disease and tissue fibrosis","volume":"208","author":"Dees","year":"2011","journal-title":"J. Exp. Med"},{"issue":"10103","key":"10.1016\/j.acthis.2023.152024_bib5","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.acthis.2023.152024_bib6","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.acthis.2023.152024_bib7","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1183\/09031936.00126907","article-title":"Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice","volume":"32","author":"Fabre","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"6 Suppl","key":"10.1016\/j.acthis.2023.152024_bib8","doi-asserted-by":"crossref","first-page":"601S","DOI":"10.1378\/chest.128.6_suppl.601S","article-title":"Abnormal vascular phenotypes in patients with idiopathic pulmonary fibrosis and secondary pulmonary hypertension","volume":"128","author":"Gagermeier","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.acthis.2023.152024_bib9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s13075-015-0848-2","article-title":"Inhibition of angiogenesis by platelets in systemic sclerosis patients","volume":"17","author":"Hirigoyen","year":"2015","journal-title":"Arthritis Res Ther."},{"issue":"11","key":"10.1016\/j.acthis.2023.152024_bib10","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1136\/annrheumdis-2016-210823","article-title":"Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis","volume":"76","author":"Huang","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.acthis.2023.152024_bib11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1183\/09031936.00185114","article-title":"Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review","volume":"46","author":"Hutchinson","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"10038","key":"10.1016\/j.acthis.2023.152024_bib12","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.acthis.2023.152024_bib13","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1164\/rccm.201903-0563CI","article-title":"Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease","volume":"201","author":"Khanna","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.acthis.2023.152024_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.678457","article-title":"Roles of macrophage polarization and macrophage-derived miRNAs in pulmonary fibrosis","volume":"12","author":"Kishore","year":"2021","journal-title":"Front Immunol."},{"issue":"11","key":"10.1016\/j.acthis.2023.152024_bib15","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1136\/thx.2009.134353","article-title":"Increased expression of 5-hydroxytryptamine2A\/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention","volume":"65","author":"Konigshoff","year":"2010","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.acthis.2023.152024_bib16","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.4049\/jimmunol.1201133","article-title":"Serotonin skews human macrophage polarization through HTR2B and HTR7","volume":"190","author":"de las Casas-Engel","year":"2013","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.acthis.2023.152024_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12931-018-0876-y","article-title":"Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis","volume":"19","author":"Lehmann","year":"2018","journal-title":"Respir. Res"},{"key":"10.1016\/j.acthis.2023.152024_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.14814\/phy2.12873","article-title":"5-HT2B receptor antagonists attenuate myofibroblast differentiation and subsequent fibrotic responses in vitro and in vivo","volume":"4","author":"Lofdahl","year":"2016","journal-title":"Physiol. Rep."},{"issue":"5","key":"10.1016\/j.acthis.2023.152024_bib19","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.ajpath.2018.01.006","article-title":"Effects of 5-Hydroxytryptamine Class 2 Receptor Antagonists on Bronchoconstriction and Pulmonary Remodeling Processes","volume":"188","author":"Lofdahl","year":"2018","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.acthis.2023.152024_bib20","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1038\/s41598-018-20430-0","article-title":"Pulmonary fibrosis in vivo displays increased p21 expression reduced by 5-HT2B receptor antagonists in vitro - a potential pathway affecting proliferation","volume":"8","author":"Lofdahl","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.acthis.2023.152024_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22010225","article-title":"Pathological insight into 5-HT2B receptor activation in fibrosing interstitial lung diseases","volume":"22","author":"Lofdahl","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.acthis.2023.152024_bib22","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.bbadis.2012.09.009","article-title":"Serotonin paracrine signaling in tissue fibrosis","volume":"1832","author":"Mann","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.acthis.2023.152024_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/biomedicines10061423","article-title":"Lung fibrosis and fibrosis in the lungs: is it all about myofibroblasts?","volume":"10","author":"Ortiz-Zapater","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.acthis.2023.152024_bib24","first-page":"58","article-title":"The levels of serum serotonin can be related to skin and pulmonary manifestations of systemic sclerosis","author":"Petric","year":"2022","journal-title":"Medicina"},{"issue":"4","key":"10.1016\/j.acthis.2023.152024_bib25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/14728214.2020.1836156","article-title":"Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials","volume":"25","author":"Roofeh","year":"2020","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.acthis.2023.152024_bib26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/ijms22052566","article-title":"The history and mystery of alveolar epithelial type II cells: focus on their physiologic and pathologic role in lung","volume":"22","author":"Ruaro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.acthis.2023.152024_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrrheum.2016.223","article-title":"Systemic sclerosis in 2016: dermal white adipose tissue implicated in SSc pathogenesis","volume":"13","author":"Varga","year":"2017","journal-title":"Nat. Rev. Rheuma"},{"issue":"3","key":"10.1016\/j.acthis.2023.152024_bib28","doi-asserted-by":"crossref","first-page":"L525","DOI":"10.1152\/ajplung.00163.2007","article-title":"mechanisms and implications for fibrotic lung disease","volume":"293","author":"Willis","year":"2007","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.acthis.2023.152024_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1183\/13993003.00161-2019","article-title":"Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases","volume":"54","author":"Wollin","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.acthis.2023.152024_bib30","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/art.1780260413","article-title":"Serotonin content of platelets in inflammatory rheumatic diseases","volume":"26","author":"Zeller","year":"1983","journal-title":"Correl. Clin. Act. Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.acthis.2023.152024_bib31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/path.5092","article-title":"An ST2-dependent role of bone marrow-derived group 2 innate lymphoid cells in pulmonary fibrosis","volume":"245","author":"Zhao","year":"2018","journal-title":"J. Pathol."},{"issue":"9","key":"10.1016\/j.acthis.2023.152024_bib32","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/cbin.10788","article-title":"M2 macrophages induce EMT through the TGF-beta\/Smad2 signaling pathway","volume":"41","author":"Zhu","year":"2017","journal-title":"Cell Biol. Int."}],"container-title":["Acta Histochemica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065128123000302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065128123000302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:14:35Z","timestamp":1758737675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065128123000302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0065128123000302"],"URL":"https:\/\/doi.org\/10.1016\/j.acthis.2023.152024","relation":{},"ISSN":["0065-1281"],"issn-type":[{"value":"0065-1281","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary 5-HT2B receptor expression in fibrotic interstitial lung diseases","name":"articletitle","label":"Article Title"},{"value":"Acta Histochemica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acthis.2023.152024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"152024"}}